Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-03

AUTHORS

Harumi Takahashi, Grant R. Wilkinson, Yoseph Caraco, Mordechai Muszkat, Richard B. Kim, Toshitaka Kashima, Sosuke Kimura, Hirotoshi Echizen

ABSTRACT

OBJECTIVE: Our objective was to investigate population differences in the metabolic activity of cytochrome P450 (CYP) 2C9 between genotypically matched Caucasian and Japanese patients by using the unbound oral clearance of S-warfarin as an in vivo phenotypic trait measure. METHODS: Ninety Japanese and 47 Caucasian patients receiving maintenance warfarin therapy were studied. Steady-state plasma unbound concentrations of S-warfarin were measured by a chiral HPLC method coupled with an ultrafiltration technique, and unbound oral clearance for S-warfarin was estimated. By combining plasma unbound concentrations of S-warfarin with the urinary excretion rates of S-7-hydroxywarfarin, the formation clearance of S-7-hydroxywarfarin was also determined. Genotyping of CYP2C9 was performed for 6 distinct alleles (CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, and a T/C transition in intron 2). RESULTS: The frequency distribution of unbound oral clearance for S-warfarin obtained from Japanese patients was shifted toward higher values as compared with that in Caucasian patients. Japanese patients had lower allelic frequencies for the 5 variants than Caucasian patients. When interpopulation comparisons of CYP2C9 activity were made for genotype-matched subjects, Japanese patients with the homozygous CYP2C9*1 (wild-type) genotype (n = 85) had significantly (P <.01) greater median values for unbound oral clearance and formation clearance than Caucasian patients with the corresponding genotype (n = 26), 10.4 mL x min(-1) x kg(-1) versus 4.25 mL x min(-1) x kg(-1) and 0.015 mL x min(-1) x kg(-1) versus 0.010 mL x min(-1) x kg(-1), respectively. In addition, Japanese patients heterozygous for the CYP2C9*3 genotype (n = 4) showed a significantly (P <.05) reduced unbound oral clearance for S-warfarin, by 63%, as compared with Japanese patients possessing the homozygous CYP2C9*1 genotype. By contrast, in Caucasian patients, no significant differences were observed in this parameter between CYP2C9(*)1 homozygous subjects and those with heterozygous CYP2C9(*)2 or CYP2C9(*)3 genotypes. CONCLUSIONS: These findings indicate that population differences in the frequencies of known variant CYP2C9 alleles account only in part for the variability observed in in vivo CYP2C9 activity in different populations. In addition, a gene-dose effect of defective CYP2C9 alleles on the in vivo CYP2C9 activity is evident in Japanese patients but not in Caucasian patients. Further studies are required to identify currently unknown factor(s) (eg, transcriptional regulation) responsible for the large intrapopulation and interpopulation variability in CYP2C9 activity. More... »

PAGES

253-263

Identifiers

URI

http://scigraph.springernature.com/pub.10.1067/mcp.2003.26a

DOI

http://dx.doi.org/10.1067/mcp.2003.26a

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051659971

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12621390


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aryl Hydrocarbon Hydroxylases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asian Continental Ancestry Group", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chromatography, High Pressure Liquid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome P-450 CYP2C9", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "European Continental Ancestry Group", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolic Clearance Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Polymorphism, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Warfarin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Meiji Pharmaceutical University", 
          "id": "https://www.grid.ac/institutes/grid.411763.6", 
          "name": [
            "Department of Pharmacotherapy, Meiji Pharmaceutical University", 
            "International Medical Center of Japan Department of Cardiovascular Surgery Tokyo", 
            "Vanderbilt University School of Medicine Division of Clinical Pharmacology Nashville", 
            "Hadassah University Hospital Department of Clinical Pharmacology Jerusalem"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takahashi", 
        "givenName": "Harumi", 
        "id": "sg:person.016673612404.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016673612404.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Meiji Pharmaceutical University", 
          "id": "https://www.grid.ac/institutes/grid.411763.6", 
          "name": [
            "Department of Pharmacotherapy, Meiji Pharmaceutical University", 
            "International Medical Center of Japan Department of Cardiovascular Surgery Tokyo", 
            "Vanderbilt University School of Medicine Division of Clinical Pharmacology Nashville", 
            "Hadassah University Hospital Department of Clinical Pharmacology Jerusalem"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilkinson", 
        "givenName": "Grant R.", 
        "id": "sg:person.01272017547.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272017547.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Meiji Pharmaceutical University", 
          "id": "https://www.grid.ac/institutes/grid.411763.6", 
          "name": [
            "Department of Pharmacotherapy, Meiji Pharmaceutical University", 
            "International Medical Center of Japan Department of Cardiovascular Surgery Tokyo", 
            "Vanderbilt University School of Medicine Division of Clinical Pharmacology Nashville", 
            "Hadassah University Hospital Department of Clinical Pharmacology Jerusalem"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Caraco", 
        "givenName": "Yoseph", 
        "id": "sg:person.01130627320.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130627320.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Meiji Pharmaceutical University", 
          "id": "https://www.grid.ac/institutes/grid.411763.6", 
          "name": [
            "Department of Pharmacotherapy, Meiji Pharmaceutical University", 
            "International Medical Center of Japan Department of Cardiovascular Surgery Tokyo", 
            "Vanderbilt University School of Medicine Division of Clinical Pharmacology Nashville", 
            "Hadassah University Hospital Department of Clinical Pharmacology Jerusalem"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Muszkat", 
        "givenName": "Mordechai", 
        "id": "sg:person.0641204051.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641204051.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Meiji Pharmaceutical University", 
          "id": "https://www.grid.ac/institutes/grid.411763.6", 
          "name": [
            "Department of Pharmacotherapy, Meiji Pharmaceutical University", 
            "International Medical Center of Japan Department of Cardiovascular Surgery Tokyo", 
            "Vanderbilt University School of Medicine Division of Clinical Pharmacology Nashville", 
            "Hadassah University Hospital Department of Clinical Pharmacology Jerusalem"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Richard B.", 
        "id": "sg:person.015716462057.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015716462057.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Meiji Pharmaceutical University", 
          "id": "https://www.grid.ac/institutes/grid.411763.6", 
          "name": [
            "Department of Pharmacotherapy, Meiji Pharmaceutical University", 
            "International Medical Center of Japan Department of Cardiovascular Surgery Tokyo", 
            "Vanderbilt University School of Medicine Division of Clinical Pharmacology Nashville", 
            "Hadassah University Hospital Department of Clinical Pharmacology Jerusalem"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kashima", 
        "givenName": "Toshitaka", 
        "id": "sg:person.0775675414.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775675414.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Meiji Pharmaceutical University", 
          "id": "https://www.grid.ac/institutes/grid.411763.6", 
          "name": [
            "Department of Pharmacotherapy, Meiji Pharmaceutical University", 
            "International Medical Center of Japan Department of Cardiovascular Surgery Tokyo", 
            "Vanderbilt University School of Medicine Division of Clinical Pharmacology Nashville", 
            "Hadassah University Hospital Department of Clinical Pharmacology Jerusalem"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kimura", 
        "givenName": "Sosuke", 
        "id": "sg:person.01143242567.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143242567.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Meiji Pharmaceutical University", 
          "id": "https://www.grid.ac/institutes/grid.411763.6", 
          "name": [
            "Department of Pharmacotherapy, Meiji Pharmaceutical University", 
            "International Medical Center of Japan Department of Cardiovascular Surgery Tokyo", 
            "Vanderbilt University School of Medicine Division of Clinical Pharmacology Nashville", 
            "Hadassah University Hospital Department of Clinical Pharmacology Jerusalem"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Echizen", 
        "givenName": "Hirotoshi", 
        "id": "sg:person.01201654463.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201654463.93"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2003-03", 
    "datePublishedReg": "2003-03-01", 
    "description": "OBJECTIVE: Our objective was to investigate population differences in the metabolic activity of cytochrome P450 (CYP) 2C9 between genotypically matched Caucasian and Japanese patients by using the unbound oral clearance of S-warfarin as an in vivo phenotypic trait measure.\nMETHODS: Ninety Japanese and 47 Caucasian patients receiving maintenance warfarin therapy were studied. Steady-state plasma unbound concentrations of S-warfarin were measured by a chiral HPLC method coupled with an ultrafiltration technique, and unbound oral clearance for S-warfarin was estimated. By combining plasma unbound concentrations of S-warfarin with the urinary excretion rates of S-7-hydroxywarfarin, the formation clearance of S-7-hydroxywarfarin was also determined. Genotyping of CYP2C9 was performed for 6 distinct alleles (CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, and a T/C transition in intron 2).\nRESULTS: The frequency distribution of unbound oral clearance for S-warfarin obtained from Japanese patients was shifted toward higher values as compared with that in Caucasian patients. Japanese patients had lower allelic frequencies for the 5 variants than Caucasian patients. When interpopulation comparisons of CYP2C9 activity were made for genotype-matched subjects, Japanese patients with the homozygous CYP2C9*1 (wild-type) genotype (n = 85) had significantly (P <.01) greater median values for unbound oral clearance and formation clearance than Caucasian patients with the corresponding genotype (n = 26), 10.4 mL x min(-1) x kg(-1) versus 4.25 mL x min(-1) x kg(-1) and 0.015 mL x min(-1) x kg(-1) versus 0.010 mL x min(-1) x kg(-1), respectively. In addition, Japanese patients heterozygous for the CYP2C9*3 genotype (n = 4) showed a significantly (P <.05) reduced unbound oral clearance for S-warfarin, by 63%, as compared with Japanese patients possessing the homozygous CYP2C9*1 genotype. By contrast, in Caucasian patients, no significant differences were observed in this parameter between CYP2C9(*)1 homozygous subjects and those with heterozygous CYP2C9(*)2 or CYP2C9(*)3 genotypes.\nCONCLUSIONS: These findings indicate that population differences in the frequencies of known variant CYP2C9 alleles account only in part for the variability observed in in vivo CYP2C9 activity in different populations. In addition, a gene-dose effect of defective CYP2C9 alleles on the in vivo CYP2C9 activity is evident in Japanese patients but not in Caucasian patients. Further studies are required to identify currently unknown factor(s) (eg, transcriptional regulation) responsible for the large intrapopulation and interpopulation variability in CYP2C9 activity.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1067/mcp.2003.26a", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2436321", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1017409", 
        "issn": [
          "0009-9236", 
          "1532-6535"
        ], 
        "name": "Clinical Pharmacology & Therapeutics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "73"
      }
    ], 
    "name": "Population differences in S\u2010warfarin metabolism between CYP2C9 genotype\u2010matched Caucasian and Japanese patients", 
    "pagination": "253-263", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f61527a01a8140f00f1368971209d2eea8b7b3c675f9c5493857771e8b065250"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12621390"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0372741"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1067/mcp.2003.26a"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051659971"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1067/mcp.2003.26a", 
      "https://app.dimensions.ai/details/publication/pub.1051659971"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8663_00000089.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://onlinelibrary.wiley.com/doi/10.1067/mcp.2003.26a/abstract"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1067/mcp.2003.26a'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1067/mcp.2003.26a'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1067/mcp.2003.26a'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1067/mcp.2003.26a'


 

This table displays all metadata directly associated to this object as RDF triples.

199 TRIPLES      20 PREDICATES      48 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1067/mcp.2003.26a schema:about N0380f57263b748158210ef937d0078b8
2 N0b9118c6c50345a29eee4ea1813baab3
3 N3ab942f33b0b400cb68baf1b6a41b48a
4 N4f27c22b496444b7b044f3f8793ff0fe
5 N54dcab020d4b4c6793f44a398665445e
6 N554001fabba847afa4366c75ee3ff5ca
7 N68dcd6686b82407998e09700e4088e2d
8 N6ec8191e4b7d479a91e84461bf7674f8
9 N731d83a776c340908cae4dc54edddf5f
10 N75a5d5d79919493d992dc57d09b056c9
11 N77b75b6290a644a1809c16af7e9fb954
12 N83cc1b355e0a4a9db8d1c5476c921966
13 N89955c652cbb4936a06ca5a49ad95268
14 N9750478a51ad482fb41a5fc6d345df79
15 Nb2d74c8e0cb0486f916fc2f7dfd95efd
16 Nd441716b30fd4770ac2e1341add59b76
17 Ne2bafe7c275e45e1b7395e50b1074912
18 Nfbf1add5c5434383853cf77d3be91fc7
19 Nfc68083a2dca4236b5b32e3fbdc9b3ba
20 anzsrc-for:11
21 anzsrc-for:1102
22 schema:author N975fb7ab21d9446abad73cff87537d47
23 schema:datePublished 2003-03
24 schema:datePublishedReg 2003-03-01
25 schema:description OBJECTIVE: Our objective was to investigate population differences in the metabolic activity of cytochrome P450 (CYP) 2C9 between genotypically matched Caucasian and Japanese patients by using the unbound oral clearance of S-warfarin as an in vivo phenotypic trait measure. METHODS: Ninety Japanese and 47 Caucasian patients receiving maintenance warfarin therapy were studied. Steady-state plasma unbound concentrations of S-warfarin were measured by a chiral HPLC method coupled with an ultrafiltration technique, and unbound oral clearance for S-warfarin was estimated. By combining plasma unbound concentrations of S-warfarin with the urinary excretion rates of S-7-hydroxywarfarin, the formation clearance of S-7-hydroxywarfarin was also determined. Genotyping of CYP2C9 was performed for 6 distinct alleles (CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, and a T/C transition in intron 2). RESULTS: The frequency distribution of unbound oral clearance for S-warfarin obtained from Japanese patients was shifted toward higher values as compared with that in Caucasian patients. Japanese patients had lower allelic frequencies for the 5 variants than Caucasian patients. When interpopulation comparisons of CYP2C9 activity were made for genotype-matched subjects, Japanese patients with the homozygous CYP2C9*1 (wild-type) genotype (n = 85) had significantly (P <.01) greater median values for unbound oral clearance and formation clearance than Caucasian patients with the corresponding genotype (n = 26), 10.4 mL x min(-1) x kg(-1) versus 4.25 mL x min(-1) x kg(-1) and 0.015 mL x min(-1) x kg(-1) versus 0.010 mL x min(-1) x kg(-1), respectively. In addition, Japanese patients heterozygous for the CYP2C9*3 genotype (n = 4) showed a significantly (P <.05) reduced unbound oral clearance for S-warfarin, by 63%, as compared with Japanese patients possessing the homozygous CYP2C9*1 genotype. By contrast, in Caucasian patients, no significant differences were observed in this parameter between CYP2C9(*)1 homozygous subjects and those with heterozygous CYP2C9(*)2 or CYP2C9(*)3 genotypes. CONCLUSIONS: These findings indicate that population differences in the frequencies of known variant CYP2C9 alleles account only in part for the variability observed in in vivo CYP2C9 activity in different populations. In addition, a gene-dose effect of defective CYP2C9 alleles on the in vivo CYP2C9 activity is evident in Japanese patients but not in Caucasian patients. Further studies are required to identify currently unknown factor(s) (eg, transcriptional regulation) responsible for the large intrapopulation and interpopulation variability in CYP2C9 activity.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N46d1647b1a67456da06d92f2edf1b3ec
30 Ncf97211430a54a8fb536b6f546d87f2d
31 sg:journal.1017409
32 schema:name Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients
33 schema:pagination 253-263
34 schema:productId N2b45c31295e248738fa84959d2143db0
35 N4a829efef7f846338908cd84f157bce8
36 Ndab2723a4070401b84d353effb498469
37 Ndce5a3d05a214349a833d484b3d886fa
38 Nfd35770a5b8646eb9b4087dce0d135b7
39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051659971
40 https://doi.org/10.1067/mcp.2003.26a
41 schema:sdDatePublished 2019-04-10T14:28
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher N7d95e7eefd76428b9dd3cde4462c71e2
44 schema:url http://onlinelibrary.wiley.com/doi/10.1067/mcp.2003.26a/abstract
45 sgo:license sg:explorer/license/
46 sgo:sdDataset articles
47 rdf:type schema:ScholarlyArticle
48 N0380f57263b748158210ef937d0078b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
49 schema:name Administration, Oral
50 rdf:type schema:DefinedTerm
51 N0b9118c6c50345a29eee4ea1813baab3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
52 schema:name Aged
53 rdf:type schema:DefinedTerm
54 N14597396518641989d368fdc07ae2072 rdf:first sg:person.015716462057.79
55 rdf:rest N838684ba15344e12875208fa54b5a3a1
56 N2b45c31295e248738fa84959d2143db0 schema:name dimensions_id
57 schema:value pub.1051659971
58 rdf:type schema:PropertyValue
59 N3ab942f33b0b400cb68baf1b6a41b48a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Chromatography, High Pressure Liquid
61 rdf:type schema:DefinedTerm
62 N46d1647b1a67456da06d92f2edf1b3ec schema:volumeNumber 73
63 rdf:type schema:PublicationVolume
64 N4a829efef7f846338908cd84f157bce8 schema:name pubmed_id
65 schema:value 12621390
66 rdf:type schema:PropertyValue
67 N4f27c22b496444b7b044f3f8793ff0fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Metabolic Clearance Rate
69 rdf:type schema:DefinedTerm
70 N54dcab020d4b4c6793f44a398665445e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Asian Continental Ancestry Group
72 rdf:type schema:DefinedTerm
73 N554001fabba847afa4366c75ee3ff5ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Male
75 rdf:type schema:DefinedTerm
76 N68dcd6686b82407998e09700e4088e2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Adult
78 rdf:type schema:DefinedTerm
79 N6ec8191e4b7d479a91e84461bf7674f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Female
81 rdf:type schema:DefinedTerm
82 N731d83a776c340908cae4dc54edddf5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Aged, 80 and over
84 rdf:type schema:DefinedTerm
85 N75a5d5d79919493d992dc57d09b056c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Anticoagulants
87 rdf:type schema:DefinedTerm
88 N77b75b6290a644a1809c16af7e9fb954 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Polymorphism, Genetic
90 rdf:type schema:DefinedTerm
91 N77fe678dbf9d4e15bc5d774f19bc1b78 rdf:first sg:person.0641204051.36
92 rdf:rest N14597396518641989d368fdc07ae2072
93 N7d95e7eefd76428b9dd3cde4462c71e2 schema:name Springer Nature - SN SciGraph project
94 rdf:type schema:Organization
95 N8072a0629d61456da9e913b24890d45d rdf:first sg:person.01130627320.74
96 rdf:rest N77fe678dbf9d4e15bc5d774f19bc1b78
97 N838684ba15344e12875208fa54b5a3a1 rdf:first sg:person.0775675414.59
98 rdf:rest Nd89e84b4a9c14a45a794a212aa8052b1
99 N83957ad256574c79bb456970d2431a51 rdf:first sg:person.01201654463.93
100 rdf:rest rdf:nil
101 N83cc1b355e0a4a9db8d1c5476c921966 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Aryl Hydrocarbon Hydroxylases
103 rdf:type schema:DefinedTerm
104 N89955c652cbb4936a06ca5a49ad95268 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Genotype
106 rdf:type schema:DefinedTerm
107 N9750478a51ad482fb41a5fc6d345df79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Warfarin
109 rdf:type schema:DefinedTerm
110 N975fb7ab21d9446abad73cff87537d47 rdf:first sg:person.016673612404.16
111 rdf:rest Nf50f80609ad14d18885927042f876e91
112 Nb2d74c8e0cb0486f916fc2f7dfd95efd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Humans
114 rdf:type schema:DefinedTerm
115 Ncf97211430a54a8fb536b6f546d87f2d schema:issueNumber 3
116 rdf:type schema:PublicationIssue
117 Nd441716b30fd4770ac2e1341add59b76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name European Continental Ancestry Group
119 rdf:type schema:DefinedTerm
120 Nd89e84b4a9c14a45a794a212aa8052b1 rdf:first sg:person.01143242567.65
121 rdf:rest N83957ad256574c79bb456970d2431a51
122 Ndab2723a4070401b84d353effb498469 schema:name nlm_unique_id
123 schema:value 0372741
124 rdf:type schema:PropertyValue
125 Ndce5a3d05a214349a833d484b3d886fa schema:name doi
126 schema:value 10.1067/mcp.2003.26a
127 rdf:type schema:PropertyValue
128 Ne2bafe7c275e45e1b7395e50b1074912 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Cytochrome P-450 CYP2C9
130 rdf:type schema:DefinedTerm
131 Nf50f80609ad14d18885927042f876e91 rdf:first sg:person.01272017547.94
132 rdf:rest N8072a0629d61456da9e913b24890d45d
133 Nfbf1add5c5434383853cf77d3be91fc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Japan
135 rdf:type schema:DefinedTerm
136 Nfc68083a2dca4236b5b32e3fbdc9b3ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Middle Aged
138 rdf:type schema:DefinedTerm
139 Nfd35770a5b8646eb9b4087dce0d135b7 schema:name readcube_id
140 schema:value f61527a01a8140f00f1368971209d2eea8b7b3c675f9c5493857771e8b065250
141 rdf:type schema:PropertyValue
142 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
143 schema:name Medical and Health Sciences
144 rdf:type schema:DefinedTerm
145 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
146 schema:name Cardiorespiratory Medicine and Haematology
147 rdf:type schema:DefinedTerm
148 sg:grant.2436321 http://pending.schema.org/fundedItem sg:pub.10.1067/mcp.2003.26a
149 rdf:type schema:MonetaryGrant
150 sg:journal.1017409 schema:issn 0009-9236
151 1532-6535
152 schema:name Clinical Pharmacology & Therapeutics
153 rdf:type schema:Periodical
154 sg:person.01130627320.74 schema:affiliation https://www.grid.ac/institutes/grid.411763.6
155 schema:familyName Caraco
156 schema:givenName Yoseph
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130627320.74
158 rdf:type schema:Person
159 sg:person.01143242567.65 schema:affiliation https://www.grid.ac/institutes/grid.411763.6
160 schema:familyName Kimura
161 schema:givenName Sosuke
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143242567.65
163 rdf:type schema:Person
164 sg:person.01201654463.93 schema:affiliation https://www.grid.ac/institutes/grid.411763.6
165 schema:familyName Echizen
166 schema:givenName Hirotoshi
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201654463.93
168 rdf:type schema:Person
169 sg:person.01272017547.94 schema:affiliation https://www.grid.ac/institutes/grid.411763.6
170 schema:familyName Wilkinson
171 schema:givenName Grant R.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272017547.94
173 rdf:type schema:Person
174 sg:person.015716462057.79 schema:affiliation https://www.grid.ac/institutes/grid.411763.6
175 schema:familyName Kim
176 schema:givenName Richard B.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015716462057.79
178 rdf:type schema:Person
179 sg:person.016673612404.16 schema:affiliation https://www.grid.ac/institutes/grid.411763.6
180 schema:familyName Takahashi
181 schema:givenName Harumi
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016673612404.16
183 rdf:type schema:Person
184 sg:person.0641204051.36 schema:affiliation https://www.grid.ac/institutes/grid.411763.6
185 schema:familyName Muszkat
186 schema:givenName Mordechai
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641204051.36
188 rdf:type schema:Person
189 sg:person.0775675414.59 schema:affiliation https://www.grid.ac/institutes/grid.411763.6
190 schema:familyName Kashima
191 schema:givenName Toshitaka
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775675414.59
193 rdf:type schema:Person
194 https://www.grid.ac/institutes/grid.411763.6 schema:alternateName Meiji Pharmaceutical University
195 schema:name Department of Pharmacotherapy, Meiji Pharmaceutical University
196 Hadassah University Hospital Department of Clinical Pharmacology Jerusalem
197 International Medical Center of Japan Department of Cardiovascular Surgery Tokyo
198 Vanderbilt University School of Medicine Division of Clinical Pharmacology Nashville
199 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...